Glenmark Pharmaceuticals Limited (Glenmark) has announced impressive financial results for the first quarter of FY 2024-25, marked by a 6.9% increase in consolidated revenue and notable improvements in profit margins. For the quarter ending June 30, 2024, Glenmark’s consolidated revenue was ₹3,244.2 crores, up from ₹3,036.1 crores in the same period last year. EBITDA surged […]
Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, today released its financial results for the fourth quarter ending March 31, 2024, showcasing a solid performance across its diversified markets despite some challenges in North America. Glenmark Pharmaceuticals Financial Highlights and Performance For the fourth quarter of FY 2023-24, Glenmark reported a consolidated revenue of Rs. […]
